Travere Therapeutics, Inc. (TVTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$65.28-1.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TVTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 591.3 | 490.7 | 233.2 | 145.2 | 109.5 | 131.8 | 198.3 | 175.3 | 164.2 | 154.9 | 133.6 | 99.9 | 28.2 | — | — | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Cost of Revenues | 8.3 | 10.3 | 7.7 | 11.5 | 4.4 | 3.8 | 6.1 | 5.2 | 5.5 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 390.6 | 337.2 | 264.1 | 265.5 | 197.5 | 126.3 | 135.8 | 129.0 | 103.7 | 101.3 | 91.9 | 79.5 | 59.6 | 17.7 | 29.6 | — |
| R&D Expenses | — | — | — | — | 7.5 | — | — | 141.0 | 123.8 | 78.2 | 70.8 | 50.4 | 47.8 | 7.1 | 0.7 | — |
| Operating Income | (40.5) | (62.8) | (323.8) | (388.1) | (319.8) | (199.4) | (176.2) | (137.4) | (80.0) | (53.8) | (58.2) | (50.7) | (79.8) | (24.8) | — | — |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 10.7 | 11.2 | 11.3 | 11.0 | 19.7 | 19.1 | 18.8 | 9.8 | 4.4 | 4.7 | 7.7 | 7.4 | 0.0 | 0.1 | — |
| Interest & Investment Income | 11.6 | 12.7 | 17.8 | 21.8 | 6.3 | 2.0 | 5.0 | 10.1 | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (10.5) | 4.7 | 17.7 | 14.1 | 8.7 | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (26.6) | 13.6 | 3.3 | 12.0 | (11.3) | (17.5) | (12.6) | (9.1) | (21.8) | (4.6) | 0.6 | 156.2 | — | (9.8) | — | — |
| Asset Writedown | — | — | 1.2 | 0.0 | 0.0 | — | — | — | — | — | — | 4.7 | — | — | — | — |
| EBT, Incl. Unusual Items | (67.1) | (49.3) | (320.5) | (376.1) | (331.2) | (216.9) | (188.8) | (146.4) | (101.9) | (58.4) | (57.6) | 105.5 | (113.4) | (34.5) | — | — |
| Income Tax Expense | 0.6 | 1.0 | 0.1 | 0.2 | 0.3 | 0.4 | (19.4) | (0.0) | 0.8 | 1.4 | (9.7) | (11.8) | (2.5) | 0.1 | — | — |
| Net Income | ||||||||||||||||
| Net Income | (43.5) | (25.5) | (321.5) | (111.4) | (278.5) | (180.1) | (169.4) | (146.4) | (102.7) | (59.7) | (47.9) | 117.2 | (110.9) | (34.6) | (30.3) | (0.0) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.46) | (0.29) | (4.08) | (1.50) | (4.37) | (3.01) | (3.56) | — | (2.54) | (1.54) | (1.29) | 3.49 | — | — | — | — |
| Diluted EPS | (0.46) | (0.29) | (4.08) | (1.50) | (4.37) | (3.01) | (3.56) | — | (2.54) | (1.54) | (1.29) | 3.17 | — | — | — | — |
| Revenue per Share | 6.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 93.5 | 89.2 | 78.9 | 74.3 | 63.8 | 59.8 | 47.5 | — | 40.4 | 38.8 | 37.0 | 33.6 | — | — | — | — |
| Diluted Weighted Avg Shares | 93.5 | 89.2 | 78.9 | 74.3 | 63.8 | 59.8 | 47.5 | — | 40.4 | 38.8 | 38.3 | 37.6 | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (2.1) | (280.3) | (349.6) | (299.1) | (186.7) | (151.6) | (117.0) | (61.4) | (36.0) | (42.1) | (37.4) | (74.4) | (24.6) | — | — |
| EBIT | (40.5) | (62.8) | (323.8) | (388.1) | (319.8) | (199.4) | (176.2) | (137.4) | (80.0) | (53.8) | (58.2) | (50.7) | (79.8) | (24.8) | — | — |
| Effective Tax Rate | -0.9% | — | — | -0.1% | -0.1% | -0.2% | 10.3% | 0.0% | -0.8% | -2.3% | 16.8% | -11.2% | 2.2% | -0.2% | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.